Search results for "gon"

showing 10 items of 6445 documents

Official and Self-Reported Childhood Abuse and Adult Crime of Young Offenders

2004

This study sought to predict adult criminal behavior in a sample of 89 young male prison inmates using self-reported and official data on childhood maltreatment (gathered from interviews and files) and criminality (collected using a 33-item Self-Reported Criminality Scale and official criminal records). Overall, the offenders convicted of violent versus nonviolent crimes did not differ in self-reported criminality. File-based neglect was predictive of self-reported property offenses, and self-reported psychological abuse predicted self-reported vandalism. Official criminal record data was not predicted by self-reported or file-based childhood maltreatment. The findings provided evidence of…

medicine.medical_specialtyCriminal recordmedia_common.quotation_subject050901 criminology05 social sciencesPoison controlHuman factors and ergonomicsPrisonsocial sciencesSuicide preventionPathology and Forensic MedicineNeglectInjury preventionmedicine0501 psychology and cognitive sciences0509 other social sciencesPsychiatryPsychologyPsychological abuseLawGeneral Psychology050104 developmental & child psychologymedia_commonCriminal Justice and Behavior
researchProduct

Body composition and muscle performance during menopause and hormone replacement therapy.

2003

Menopausal transition is characterized by ovarian failure and its consequent decrease in female sex steroid production. Earlier studies suggest that an increase and redistribution of body fat during menopause predispose women to cardiovascular disease and metabolic syndrome. In addition, peri- and post-menopausal women seem to have less lean body mass (LBM) compared with pre-menopausal women. Accordingly, a changing ovarian hormonal status may accelerate the loss of muscle mass and result in decreased muscle performance and functional capacity. Hormone replacement therapy (HRT) has been used to treat menopausal symptoms and as a primary prevention therapy in chronic conditions. Inconsistent…

medicine.medical_specialtyCross-sectional studyHormone Replacement TherapyEndocrinology Diabetes and MetabolismDiseaseEndocrinologyInternal medicinemedicineHumansGonadal Steroid HormonesMuscle SkeletalAgedbusiness.industryMiddle Agedmedicine.diseaseDuring menopauseMenopauseEndocrinologyCross-Sectional StudiesTransgender hormone therapyLean body massBody CompositionFemalesense organsMetabolic syndromeMenopausebusinessHormoneJournal of endocrinological investigation
researchProduct

Participatory Ergonomics: A Model for the Prevention of Occupational Musculoskeletal Disorders

2009

La ergonomía participativa es una estrategia de intervención sobre los riesgos por carga física en los lugares de trabajo escasamente conocida en España, aunque en otros países se cuenta con numerosas experiencias y evidencias en este campo. Son varias las razones que justifican su interés. En primer lugar, aborda una de las categorías de riesgos laborales que mayor impacto tiene sobre la salud de los trabajadores en la mayoría de países, tanto en términos de incidencia, como de prevalencia o incapacidad. En segundo lugar, el principio básico de la ergonomía participativa es la capacitación de los trabajadores para que participen tanto en la identificación de los riesgos y daños a la salud …

medicine.medical_specialtyCumulative Trauma Disordersmedia_common.quotation_subjectControl (management)Psychological interventionlcsh:MedicineAutodeterminaciónNursingmedicineParticipación trabajadoresSociologyErgonomíaEmpowermentDiscapacidad física y orgánicaOccupational HealthWorkersmedia_commonDemocraciaTrastornos musculoesqueléticosPublic healthlcsh:Public aspects of medicinelcsh:RSalud laborallcsh:RA1-1270General MedicineParticipatory ergonomicsDemocracyIntervention (law)PrevenciónWork (electrical)Physical loadTrabajadoresErgonomicsEnfermedades profesionalesEntorno laboralRevista Española de Salud Pública
researchProduct

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre st…

2016

Ajuda rebuda: GlaxoSmithKline Several glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1Ra) have been made recently available in Spain for type 2 diabetes mellitus (DM2) treatment. There are no published data on the clinical and sociodemographic profile of patients initiating treatment with GLP-1Ra in Spain. Our objective was to understand these patients' characteristics in a real-world clinical practice setting. Design. Cross-sectional observational study. Setting. Spanish specialist outpatient clinics.Participants 403 adults with DM2 initiating GLP-1Ra treatment were included. Primary and secondary outcome measures Sociodemographic and DM2-related clinical data, including treatment …

medicine.medical_specialtyDM2Cross-sectional studymedicine.medical_treatment030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineInsulinaInternal medicinemedicineOutpatient clinic030212 general & internal medicineMedical prescriptionGlucagon-like peptide 1 receptorDiabetisbusiness.industryInsulinDiabetis mellitus tipus 2Type 2 Diabetes MellitusGeneral MedicineDiabetes mellitus tipo 2EndocrinologyConcomitantMalalties d'origen nutricionalbusinessBody mass index
researchProduct

Peritoneal cavity phagocytes from the teleost sea bass express a glucocorticoid receptor (cloned and sequenced) involved in genomic modulation of the…

2005

Abstract To gain further insight into the role of cortisol in Wsh innate immune responses, we cloned and sequenced a 2592 bp cDNA from sea bass (Dicentrarchus labrax) peritoneal leukocytes (PCLs) encoding a glucocorticoid receptor (DlGR1). The deduced aminoacid sequence displayed that DlGR1 belong to a multigenic family of steroid hormone receptors, and exhibited high homology (80%) to the Burton’s mouth breeder (Haplochromis burtoni) HbGR1. The DlGR1 functional domains presented homologies with those of several vertebrate species. In situ hybridization assay revealed that DlGR1 was expressed in macrophages and neutrophils from the peritoneal cavity. Since in a previous paper, sea bass PCL …

medicine.medical_specialtyDNA ComplementaryHydrocortisonemedicine.medical_treatmentMolecular Sequence DataDicentrarchus labrax; Peritoneal cavity leukocytes; Phagocytes; Hydrocortisone; RU486; Glucocorticoid receptor; DlGR1; GR cDNA sequence; GR mRNA expressionSequence HomologyGlucocorticoid receptorBiologyDlGR1Peritoneal cavitychemistry.chemical_compoundEndocrinologyGlucocorticoid receptorReceptors GlucocorticoidInternal medicinemedicineAnimalsDicentrarchus labraxPeritoneal cavity leukocyteAmino Acid SequenceSea bassReceptorPeritoneal CavityCells CulturedRespiratory BurstPhagocytesInnate immune systemDose-Response Relationship DrugZymosanZymosanMolecular biologyRespiratory burstSteroid hormoneGR mRNA expressionmedicine.anatomical_structureEndocrinologychemistryPhagocyteLuminescent MeasurementsGR cDNA sequenceAnimal Science and ZoologyBasshormones hormone substitutes and hormone antagonistsStress PsychologicalRU486
researchProduct

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Incretin-based therapies in 2021 – Current status and perspectives for the future

2021

medicine.medical_specialtyDipeptidyl-Peptidase IV Inhibitorsbusiness.industryEndocrinology Diabetes and MetabolismMEDLINEIncretinDiabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents IncretinsIncretinsGlucagon-Like Peptide-1 ReceptorArticleEndocrinologyDiabetes Mellitus Type 2Internal medicinemedicineHumansHypoglycemic AgentsCurrent (fluid)Intensive care medicinebusiness
researchProduct

Country of residence, gender equality and victim blaming attitudes about partner violence: a multilevel analysis in EU

2017

Background: Intimate partner violence against women (IPVAW) is a global and preventable public health problem. Public attitudes, such as victim-blaming, are important for our understanding of differences in the occurrence of IPVAW, as they contribute to its justification. In this paper, we focus on victim-blaming attitudes regarding IPVAW within the EU and we apply multilevel analyses to identify contextual determinants of victim-blaming attitudes. We investigate both the general contextual effect of the country and the specific association between country level of gender equality and individual victim-blaming attitudes, as well as to what extend a possible general contextual effect was exp…

medicine.medical_specialtyDiscriminatory accuracyeducationSocial SciencesPoison controlIntimate partner violence against women (IPVAW)Victim-blaming attitudesAffect (psychology)Multilevel analysis03 medical and health sciences0302 clinical medicinemedicinemedia_common.cataloged_instance030212 general & internal medicineEuropean unionhealth care economics and organizations0505 lawmedia_commonPublic health05 social sciencesMultilevel modelPublic Health Environmental and Occupational HealthSamhällsvetenskapHuman factors and ergonomicshumanitiesCountry differencesbehavior and behavior mechanisms050501 criminologyDomestic violenceResidencePsychologySocial psychologyEuropean Journal of Public Health
researchProduct

D1 receptors play a major role in the dopamine modulation of mouse ileum contractility

2010

Since the role of dopamine in the bowel motility is far from being clear, our aim was to analyse pharmacologically the effects of dopamine on mouse ileum contractility. Contractile activity of mouse ileum was examined in vitro as changes in isometric tension. Dopamine caused a concentration-dependent reduction of the spontaneous contraction amplitude of ileal muscle up to their complete disappearance. SCH-23390, D1 receptor antagonist, which per se increased basal tone and amplitude of spontaneous contractions, antagonized the responses to dopamine, whilst sulpiride or domperidone, D2 receptor antagonists, were without effects. The application of both D1 and D2 antagonists had additive effe…

medicine.medical_specialtyDopamineMouse ileumD1 receptorIn Vitro TechniquesSettore BIO/09 - FisiologiaEnteric Nervous SystemPotassium channelsContractilityMicechemistry.chemical_compoundDopamine receptor D1IleumDopamineInternal medicineDopamine receptor D2medicineAnimalsPharmacologySCH-23390Dose-Response Relationship DrugReceptors Dopamine D1BenzazepinesAdenosine receptorContractile activityD2 receptorDopamine D2 Receptor AntagonistsEndocrinologychemistryDopamine receptorDopamine AntagonistsEndogenous agonistAdenylyl CyclasesMuscle Contractionmedicine.drugPharmacological Research
researchProduct

Prolonged-release buprenorphine formulations: Perspectives for clinical practice

2020

International audience; Buprenorphine and methadone are the two main opioid agonist treatments approved for opioid use disorder. Buprenorphine is a partial agonist of the mu opioid receptors, which has been merely available through sublingual form until now. In practice, the use of buprenorphine is smoother than that of methadone, and it induces reduced risks of overdose. However, sublingual buprenorphine also exposes to risks (e.g., withdrawal, misuse) and constraints (e.g., daily intake). Three new galenic formulations of prolonged-release buprenorphine (PRB) are being commercialized and should allow some improvements in patients' comfort and safety. This narrative review aims to describe…

medicine.medical_specialtyDoseNarcotic Antagonists[SDV.MHEP.PSM] Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthReceptors Opioid mu030226 pharmacology & pharmacyPartial agonistOpioid dependenceDependance aux opioides03 medical and health sciencesSubcutaneous injection0302 clinical medicineProlonged releasemedicineHumansProlonged-releasePharmacology (medical)OpiacésAction prolongeebusiness.industryOpioid use disorderOpioid-Related Disordersmedicine.disease3. Good healthBuprenorphineAnalgesics OpioidOpiatesOpioid[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental healthEmergency medicinebusinessSubstitutionMethadoneBuprenorphinemedicine.drugMethadone
researchProduct